A 364

Drug Profile

A 364

Latest Information Update: 03 May 2004

Price : $50

At a glance

  • Originator Arrow Therapeutics
  • Class Antibacterials
  • Mechanism of Action Dehydroquinate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Gram-positive infections

Most Recent Events

  • 03 May 2004 Discontinued - Preclinical for Gram-positive infections in United Kingdom (unspecified route)
  • 13 Jan 2002 New profile
  • 13 Jan 2002 Preclinical development for Gram-positive infections in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top